The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Pharmacologic properties of (-)-3PPP (preclamol) in man.
C A Tamminga; N G Cascella; R A Lahti; M Lindberg; A Carlsson (Profiled Author: Nicola Cascella)
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore.
Journal of neural transmission. General section 1992;88(3):165-75.
The dopamine (DA) autoreceptor agonist (-)-3PPP (preclamol) was tested in male schizophrenic volunteers for safety. The drug was administered intramuscularly in a single rising dose design, crossed with a similar "rising dose" placebo period; all evaluations and raters were blind to drug or placebo administration. Pharmacokinetic, endocrine, safety, and mental status outcome measures were completed before and after each single dose of drug or placebo. Pharmacokinetic analysis showed blood levels between 200-500 pmoles/ml after the intramuscular drug doses of 30-40 mg. Drug half life is 2-2.5 hrs. Growth hormone (GH) levels were elevated in a linear fashion to the 30 mg dose; whereafter, the drug failed to affect GH at all. All safety evaluations were negative, including any untoward effects on the major organ systems. After single dose drug administration, evidence of antipsychotic action occurred in two of the four subjects. This study suggests that (-)-3PPP/preclamol is a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Deanna L Kelly; David A Gorelick; Robert R Conley; Douglas L Boggs; Jared Linthicum; Fang Liu; Stephanie Feldman; M Patricia Ball; Heidi J Wehring; Robert P McMahon; et al.Journal of clinical psychopharmacology 2011;31(1):86-91.
L E Tune; D F Wong; G Pearlson; M Strauss; T Young; E K Shaya; R F Dannals; A A Wilson; H T Ravert; J SappPsychiatry research 1993;49(3):219-37.
A Breier; O M Wolkowitz; A R Doran; A Roy; J Boronow; D W Hommer; D PickarThe American journal of psychiatry 1987;144(12):1549-55.
Appears in this Publication
Author of this Publication